Evidence map›Paper›PMID 41210445›Full record

ArticleAME case reports2025

Application of methylene blue injection staining in the diagnosis of hepatic pleural effusion in patients with cirrhosis-a case report and literature review.

Zhaoyang Xing, Hui Wang

Abstract readCase Reports
In one paragraph

Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Zhaoyang XingDepartment of Critical Medicine, the First People's Hospital of Guangyuan, Guangyuan, China.ORCID https://orcid.org/0000-0003-0476-2080
Hui WangClinical Medical Department, the Third People's Hospital of Guangyuan, Guangyuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatic pleural effusion is a common complication in patients with cirrhosis. The diagnosis of hepatic pleural effusion is limited by many factors. There are advantages and disadvantages to using radioisotope examination, contrast-enhanced ultrasound and video-assisted thoracoscopy surgery in detecting diaphragmatic defects. We reported that methylene blue injection was injected into the peritoneal cavity, and pleural effusion was turned pale blue with methylene blue. We inferred diaphragmatic rupture in patients with hepatic pleural effusion. Methylene blue injection staining is a supplementary method for the diagnosis of diaphragmatic rupture in patients with hepatic pleural effusion. Case Description: The patient is an 83-year-old patient who was admitted to hospital with respiratory failure. The ultrasound showed a large right pleural effusion and ascites. A computed tomography scan showed no lung infection. The patient has cirrhosis for 20 years. We performed endotracheal intubation and mechanical ventilation. A drainage tube was placed in the patient's right pleural cavity. We injected 2 mL of methylene blue into the patient's peritoneal cavity. After 2 hours, the right pleural cavity drainage appears light blue. Based on this, we assume the patient's diaphragm ruptured. The patient was diagnosed with hepatic pleural effusion. We did a comprehensive treatment for the pleural effusion. Repeated increase of pleural effusion. The patient died 62 days after admission. Conclusions: Methylene blue injection staining is a supplementary method for the diagnosis of diaphragmatic rupture in patients with hepatic pleural effusion. It is suitable for areas lacking detection methods.

Indexed as

case reportcirrhosishydrothoraxmethylene bluePleural effusion

Identifiers

PMID41210445
PMCPMC12593179

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.